This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Abbvie, other drug firms asked by US Senator Klobuchar to remove improperly listed patents

( January 18, 2024, 23:02 GMT | Official Statement) -- MLex Summary: US Senator Amy Klobuchar sent letters to pharmaceutical companies Abbvie, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan-Viatris and Teva asking them to remove, by the end of the month,  all patents identified by the Federal Trade Commission as improperly or inaccurately listed in the Food and Drug Administration Orange Book. "While your inventions that benefit consumers deserve strong patent protections, those patents should not be used to box out generic drug competition long after legitimate patent protections have expired," Klobuchar wrote in the letters. Improperly listing a patent in the Orange Book can harm consumers, raise prices, and stifle competition by preventing cheaper generic drugs from entering the market for up to 30 months, she said.See statement below and attached documents....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login